Immunotherapy in gastric cancer

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1657-1666

  Matsueda, Satoko ^a   Graham, David Y ^b  

^a KURUME UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adoptive cell therapy; Antibody therapy; Cancer vaccine; Gastric cancer; Immune checkpoint; Immune escape; Predictive biomarker

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTIBODY; IMMUNOSUPPRESSIVE AGENT; RNA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL PROLIFERATION; CELL THERAPY; CYTOTOXICITY; GENE THERAPY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; STOMACH CANCER; SURVIVAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CHEMISTRY; CYTOLOGY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE ACTIVATION; PROCEDURES; STOMACH NEOPLASMS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CANCER VACCINES; CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; LYMPHOCYTE ACTIVATION; RNA; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 84894284180     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1657     Document Type: Article

References (69)

1. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012; 143: 550-563 [PMID: 22796521 DOI: 10.1053/ j.gastro.2012.07.009.]
2. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J 1957; 1: 779-786 [PMID: 13404306]
3. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154-158 [PMID: 16789469]
4. Vollmers HP, Dämmrich J, Ribbert H, Wozniak E, Müller-Hermelink HK. Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 1995; 76: 550-558 [PMID: 8625146]
5. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 1985; 75: 595-603 [PMID: 3876465]
6. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science 1986; 233: 1318-1321 [PMID: 3489291]
7. Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49: 4770-4774 [PMID: 2527087]
8. Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C, Foddai ML, Lorusso D, Martinelli E, Vacca M, Ipsevich F, Nuti M, Scambia G, Pierelli L. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 2012; 14: 841-850 [PMID: 22563888 DOI: 10.3109/1465 3249.2012.681038]
9. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492 [PMID: 3903508]
10. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23: 488-496 [PMID: 19544689]
11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897 [PMID: 3493432]
12. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Inoue M, Tamai M. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumorinfiltrating lymphocytes]. Nihon Gan Chiryo Gakkai Shi 1990; 25: 978-989 [PMID: 2391445]
13. Alexander RB, Rosenberg SA. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 1990; 145: 1615-1620 [PMID: 1974569]
14. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002; 8: 1767-1771 [PMID: 12060615]
15. Tsoukas CD, Landgraf B, Bentin J, Valentine M, Lotz M, Vaughan JH, Carson DA. Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J Immunol 1985; 135: 1719-1723 [PMID: 3926881]
16. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokineinduced killer cells. Anticancer Res 2006; 26: 2237-2242 [PMID: 16821594]
17. Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16: 6155-6162 [PMID: 21182234]
18. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296 [PMID: 1910679]
19. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998; 78: 202-208 [PMID: 9754653]
20. Nguyen T, Naziruddin B, Dintzis S, Doherty GM, Mohanakumar T. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. Int J Cancer 1999; 81: 607-615 [PMID: 10225452]
21. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J 2000; 6: 69-77 [PMID: 11069222]
22. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854 [PMID: 12242449]
23. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-1457 [PMID: 1402688]
24. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930 [PMID: 8113684]
25. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 3038-3043 [PMID: 7805731]
26. Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996; 43: 377-383 [PMID: 8606058]
27. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997; 57: 4465-4468 [PMID: 9377553]
28. Yang J, Li ZH, Zhou JJ, Chen RF, Cheng LZ, Zhou QB, Yang LQ. Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice. Chin J Cancer 2010; 29: 359-364 [PMID: 20346208]
29. Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, Takeda K, Yoshida K, Tsunoda T, Nakamura Y, Mori M, Doki Y. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol 2012; 41: 1297-1304 [PMID: 22842485 DOI: 10.3892/ijo.2012.1573]
30. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472 [PMID: 8760800]
31. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432-1442 [PMID: 16612595]
32. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA-and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115: 33-42 [PMID: 18006079]
33. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30: 1-7 [PMID: 10602021]
34. Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG, Pascolo S. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61: 2418-2424 [PMID: 15378210]
35. Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000; 114: 632-636 [PMID: 10733665]
36. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70: 9031-9040 [PMID: 21045153 DOI: 10.1158/0008-5472.CAN-10-0699]
37. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34: 1-15 [PMID: 21150709 DOI: 10.1097/ CJI.0b013e3181f7dbe8]
38. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31: 180-188 [PMID: 18481387 DOI: 10.1097/CJI.0b013e31815ce501]
39. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32: 498-507 [PMID: 19609242 DOI: 10.1097/CJI.0b013e3181a00068]
40. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19: 990-999 [PMID: 21189474 DOI: 10.1038/mt.2010.289]
41. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-299 [PMID: 11276199]
42. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384 [PMID: 11357146]
43. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997; 186: 229-238 [PMID: 9221752]
44. Antonia SJ, Extermann M, Flavell RA. Immunologic nonresponsiveness to tumors. Crit Rev Oncog 1998; 9: 35-41 [PMID: 9754446]
45. Villunger A, Strasser A. The great escape: is immune evasion required for tumor progression? Nat Med 1999; 5: 874-875 [PMID: 10426306]
46. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 1999; 48: 382-385 [PMID: 10501851]
47. Lee HW, Min SK, Ju YS, Sung J, Lim MS, Yang DH, Lee BH. Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5. J Gastrointest Surg 2011; 15: 1336-1343 [PMID: 21512844. DOI: 10.1007/s11605-011-1545-3]
48. Kandulski A, Malfertheiner P, Wex T. Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer. Anticancer Res 2010; 30: 1093-1103 [PMID: 20530414]
49. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, Mori M. Cancer stem cells in human gastrointestinal cancers. Hum Cell 2006; 19: 24-29 [PMID: 16643604]
50. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128: 1567-1578 [PMID: 15887152]
51. Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 2013; 4: 70 [PMID: 23763837 DOI: 10.1186/scrt221]
52. Lin R, Ma H, Ding Z, Shi W, Qian W, Song J, Hou X. Bone marrow-derived mesenchymal stem cells favor the immunosuppressive T cells skewing in a Helicobacter pylori model of gastric cancer. Stem Cells Dev 2013; 22: 2836-2848 [PMID: 23777268]
53. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1104621]
54. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047 [PMID: 22271879 DOI: 10.1158/1078-0432. CCR-11-1823]
55. Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120: 157-167 [PMID: 20038811 DOI: 10.1172/JCI40070]
56. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012; 30: 3234-3241 [PMID: 22649126. DOI: 10.1200/JCO.2011.40.5902]
57. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 [PMID: 22149875 DOI: 10.1056/NEJMoa1113216]
58. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009 [PMID: 12490681]
59. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Geneexpression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010; 9: 555-565 [PMID: 20518712. DOI: 10.1586/erv.10.55]
60. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106: 20429-20434 [PMID: 19915147 DOI: 10.1073/pnas.0905139106]
61. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Bogaev RC, Elashoff B, Baron H, Yee J, Valantine HA. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362: 1890-1900 [PMID: 20413602 DOI: 10.1056/NEJMoa0912965]
62. Chaussabel D, Pascual V, Banchereau J. Assessing the human immune system through blood transcriptomics. BMC Biol 2010; 8: 84 [PMID: 20619006 DOI: 10.1186/1741-7007-8-84]
63. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012; 18: 2780-2790 [PMID: 22589486 DOI: 10.1158/1078-0432. CCR-11-1920]
64. Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE. Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 2012; 907: 645-666 [PMID: 22907378 DOI: 10.1007/978-1-61779-974-7_36]
65. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851 [PMID: 20179677 DOI: 10.1038/mt.2010.24]
66. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18: 666-668 [PMID: 20357779 DOI: 10.1038/mt.2010.31]
67. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720 [PMID: 22160384 DOI: 10.1182/ blood-2011-10-384388]
68. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6: 47 [PMID: 23829929. DOI: 10.1186/1756-8722-6-47]
69. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998 [PMID: 12407406 DOI: 10.1038/ ni1102-991]